A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2004
11/25/2004	WO2004100957A1 Treatment of bipolar disorders and associated symptoms
11/25/2004	WO2004100956A1 Method for enhancing cognition using ziprasidone
11/25/2004	WO2004100955A1 Anxiety treatments with ziprasidone
11/25/2004	WO2004100954A1 Treatment of psychotic and depressive disorders
11/25/2004	WO2004100951A1 Diabetic neuropathy diagnostic and therapeutic
11/25/2004	WO2004100948A1 Further therapeutic use of zolpidem
11/25/2004	WO2004100943A1 Use of triglyceride oils containing gamma-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease
11/25/2004	WO2004100940A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression
11/25/2004	WO2004100939A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression
11/25/2004	WO2004100938A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression
11/25/2004	WO2004100937A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression
11/25/2004	WO2004089942A3 Benzimidazolidinone derivatives as muscarinic agents
11/25/2004	WO2004071416B1 Novel inhibitors of formation of advanced glycation endproducts (ages)
11/25/2004	WO2004067002A3 SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT
11/25/2004	WO2004064753A3 Use of n-desmethylclozapine to treat human neuropsychiatric disease
11/25/2004	WO2004064738A3 Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
11/25/2004	WO2004018386A3 Acetophenone potentiators of metabotropic glutamate receptors
11/25/2004	WO2003082906A3 Neurotrophic and neuroprotective peptides
11/25/2004	WO2003070197A3 RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/25/2004	WO2003000849A3 Methods for representing sequence-dependent contextual information present in polymer sequences and uses thereof
11/25/2004	US20040237127 Composition and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis and abnormal cell proliferation
11/25/2004	US20040236147 Integrin antagonist; antiinflammatory agents; antiarthritic agents; inflammatory bowel disease; lupus; multiple sclerosis; asthma; psoriasis;antidiabetic agents; cardiovascular disorders
11/25/2004	US20040236116 Novel bicyclic and tricyclic cannabinoids
11/25/2004	US20040236108 Bicarbocyclic hydrazine/hydrazide compounds as inhibitors of semicarbazide-sensitive amine oxidases (SSAO); treat an inflammatory disease or condition, related to carbohydrate metabolism, smooth muscle cell function; chemical synthesis
11/25/2004	US20040236104 Substituted 4-aminocyclohexanols
11/25/2004	US20040236102 Enzyme inhibitor for treating a non-insulin dependent diabetes mellitus; 3-Amino-4-(3,4-difluorophenyl)butanoyl]-4-[2-({3-[(methylsulfonyl)amino]-phenyl}-amino)-2-oxoethyl]piperazin-2-yl}acetic acid
11/25/2004	US20040236101 Heteroindanes a new class of potent cannabimimetic ligands
11/25/2004	US20040236100 For therapy of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis
11/25/2004	US20040236073 A polypeptide with at least one amino acid replacement at position at 132, 134, 170, or 181; agonist of MET receptor
11/25/2004	US20040235962 Conformationally restricted polyamine analogs as disease therapies
11/25/2004	US20040235957 Use of sulfonamide derivatives as pharmaceuticals compounds
11/25/2004	US20040235947 Neuroprotective composition and uses thereof
11/25/2004	US20040235938 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
11/25/2004	US20040235936 Analgesics; anesthetics; antiinflammatory agents; central nervous system duisorders; strokes; antiarthritic agents; inflammatory bowel disorders
11/25/2004	US20040235933 Administering aromatic or heteroaromatic substituted indolealkanoic acid derivataives for the treatment of chronic complications arising from diabetes mellitus e.g. diabetic cataracts, retinopathy, nephropathy and neuropathy
11/25/2004	US20040235930 Indole derivatives and their use for the treatment of osteoporosis amongst other applications
11/25/2004	US20040235924 antidepressants; anxiolytic agents; eating disorders; post-traumatic stress disorders; headaches;drug addition; antiinflammatory agents
11/25/2004	US20040235921 6-substituted 2,3-dihydro-1,4-benzodioxine, 2-position substituted with carboxy, or (C1 C6)alkoxycarbonyl; diabetes, obesity; 6-[2-(R)-[2-(S)-hydroxy-3-(4-hydroxy-3-methanesulfonamido-phenoxy)propylamino]propyl]-2,3-dihydro-1,4-benzodioxine-2-(R)-carboxylic acid; B3 andrenergic receptor agonist
11/25/2004	US20040235920 Novel use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders
11/25/2004	US20040235919 Useful in treating cell proliferative disorders associated with an altered cell cycle dependent kinase activity; cancer, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders
11/25/2004	US20040235915 Benzothiazole derivatives
11/25/2004	US20040235906 Substituted amine derivatives and their use as monoamine neurotransmitter re-up-take inhibitors
11/25/2004	US20040235899 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
11/25/2004	US20040235897 3-[(1-benzyl-piperidin-4-yl)-(4-diethylcarbamoyl-phenyl)-amino]-benzamide used as opiod receptor agonists having improved pharmacokinetic, bioavailability, stability and/or lower toxicity; analgesisc; anxiolytic agents
11/25/2004	US20040235896 Certain azacycloalkyl substituted acetic acid derivatives
11/25/2004	US20040235894 N-[[4-(2-Chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl benzenesulfonamide, used for prophylaxis of asthma and/or rhinitis; respiratory system disorders
11/25/2004	US20040235889 administering imidazole, alanine, phenylalanine, substituted ethylamines, phenethylamine, histamine, histidine and linked di-imidazoles, that potentiate intraneuronal enzyme lyases; prophylaxis of neurodegenerative disorders
11/25/2004	US20040235884 increasing choline transporters on the cell membrane of nervous systems by administering drugs such as 2-(2-oxopyrrolidin-1-yl)-N-(2,3dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4yl)acetamide; prophylaxis of nervous system disorders
11/25/2004	US20040235871 A hexahydro-1,5,6,8-tetraaza-acenaphthylene or -1,3,4-triazaphenalene derivatives; treatment of depression and anxiety; inflammatory bowel disease; treatment of conditions mediated by corticotropin-releasing factor
11/25/2004	US20040235868 Purine derivatives having, in particular, anti-proliferative properties and their biological uses
11/25/2004	US20040235866 Lymphocytic activation inhibitor and remedial agent for autoimmune disease
11/25/2004	US20040235864 Jun kinase inhibitors
11/25/2004	US20040235863 As stimulators for soluble guanylate cyclase and to their use as agents in the therapy of cardiovascular diseases, hypertonicity, thrombo-embolic diseases and ischemia, sexual dysfunction or inflammations and for the treatment of diseases of the central nervous system
11/25/2004	US20040235862 Protein kinase inhibitors
11/25/2004	US20040235859 Novel piperazine derivatives
11/25/2004	US20040235858 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
11/25/2004	US20040235854 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity
11/25/2004	US20040235853 Therapeutic agents useful for treating pain
11/25/2004	US20040235851 Nitrogen compounds such as 6-[4-(5-Fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-ylmethyl]-7,8-dihydro-6H-5-oxa-1aza-phenanthrene and/or stereoisomers, used as serotonin receptor antagonists; anxiolytic agents
11/25/2004	US20040235850 Pharmaceutical compositions of varenicline
11/25/2004	US20040235849 For therapy and prophylaxis of states of pain
11/25/2004	US20040235848 Phenylalanine derivatives
11/25/2004	US20040235845 Use of phosphodiesterase iv inhibitors
11/25/2004	US20040235843 For therapy of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy
11/25/2004	US20040235842 For therapy of Alzheimer's disease, depression
11/25/2004	US20040235838 Use of 2-alkoxyphenol-substituted imidazotriazinones
11/25/2004	US20040235837 Method for treating fibrotic diseases or other indications IE
11/25/2004	US20040235832 Sexual diosrders; schizophrenia; drug abuse; eating disorders anxiolytic agents
11/25/2004	US20040235830 Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases
11/25/2004	US20040235828 For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases
11/25/2004	US20040235825 Administering compounds such as N-[4-[2-[2-(1-naphthyl)propanoylamino]phenyl]butanoyl]-(3,5-dimethylisoxazol-4-yl)sulfonamide for prophylaxis and therapy of pain, allodynia, hyperalgesia, pruritus, urticaria, atopic dermatitis, contact dermatitis, allergic conjunctivitis, asthma, rhinitis, sneeze
11/25/2004	US20040235819 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease.
11/25/2004	US20040235818 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/25/2004	US20040235816 Administering compounds such as 1-benzhydryl-3-[(methylsulfonyl)(phenyl)methylene]azetidine for therapy of schizophrenia, Parkinson's disease, and Alzeimer's disease
11/25/2004	US20040235814 Administering compounds such as 1-[1-methylene-4-(bromo-methylene)phenylene]-4,8,11-tris(diethoxyphosphoryl-1,4,8,11-tetraazacyclotetra-decane to modulate a chemokine receptor
11/25/2004	US20040235813 Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
11/25/2004	US20040235805 Administering betulinic acid or derivatives thereof for therapy or prophylaxis of anxiety
11/25/2004	US20040235795 Administration of an agent produced from phosphatidylserine (PS), lyso-phosphatidylserine or/and a physiologically acceptable salt thereof in combination with additive selected from a group comprising antioxidants, essential fatty acids, mineral substances, amino acids, mood-lifters, phospholipids
11/25/2004	US20040235764 Methods of inhibiting expression of a target gene in mammalian cells
11/25/2004	US20040235722 Assay that makes use of the interaction of early pregnancy factor (EPF) or an EPF-related peptide with a human dorsal root receptor (hDRR) or hDRR related receptor; also useful to determine whether the test compound is an agonist or antagonist of hDRRs
11/25/2004	US20040235720 May also be used in combination with an interferon for treatment and/or prevention of diseases such as traumatic nerve injury, stroke, demyelinating diseases of the CNS or PNS, neuropathies and neurodegenerative diseases
11/25/2004	US20040235718 Use of Afamin, in particular in combination with vitamin E, is for treatment of oxidative stress; treatment of Alzheimer's Disease, Huntington's Disease or amyotropic lateral sclerosis
11/25/2004	US20040235158 Using size exclusion and cell surface marker discrimination to separate and generate homogenous cell population for use in tissue replacement therapies associated with nervous system disorders
11/25/2004	US20040235123 Transgenic escherichia for use as bioreactor in fermentation of alpha-lipoic acid for use in animal feeds, medicines and cosmetics
11/25/2004	US20040235074 Methods for the treatment or prevention of immune disorders using anti-CD40 antibodies
11/25/2004	US20040234674 Artichoke leaf extracts
11/25/2004	US20040234601 Absorption in upper part oof digestive system; oral administering
11/25/2004	US20040234587 Biomass; animal extracts; anticancer agents; learning enhancing
11/25/2004	US20040234585 multilayer lamination; reducing smoking
11/25/2004	US20040234583 Transdermal therapeutic system (tts) with fentanyl as a active ingredient
11/25/2004	US20040234544 Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals
11/25/2004	US20040234527 Peptides for use as translocation factors
11/25/2004	US20040234522 therapy, diagnosis of immunology diseases; response to antigenic stimulants; cell differentiation of lymphocytes
11/25/2004	US20040234312 Bit mask generation system
11/25/2004	DE20220982U1 Transdermal patch, useful for administering fentanyl or its analog through the skin, comprises a backing layer on which a reservoir containing a single phase polymeric composition is disposed
11/25/2004	DE10320785A1 6-Arylmethyl-substituierte Pyrazolopyrimidine 6-arylmethyl-substituted pyrazolopyrimidines
11/25/2004	DE102004004142A1 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine 6-Cyclylmethyl- and 6-substituted-alkylmethyl pyrazolopyrimidines
11/25/2004	CA2625837A1 Method for enhancing cognition using ziprasidone
11/25/2004	CA2617420A1 Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
11/25/2004	CA2526458A1 Further therapeutic use of zolpidem

1 ... 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 ... 1833